Abstract
At this year's ESMO virtual congress, as every year, a number of communications were devoted to the treatment of bronchogenic cancer. There were also reports focused on immunotherapy of non-small cell lung cancer.
The efficacy of immunotherapy in this diagnosis is confirmed by updated five-year data from study KEYNOTE-024. The results of studies adding antiangiogenic therapy to checkpoint inhibitors are also encouraging.
Data from a phase III study with cemiplimab were also presented, on the basis of which we can expect the expansion of immunotherapy in patients with high PD-L1 expression.